Equita upgrades Diasorin, sees 'solid' Q3

Diasorin

Wed 10:03

** Equita upgrades its rating on Diasorin DIAS.MI to "buy" from "hold" as it expects the Italian diagnostics group to report "solid" Q3 results and confirm FY outlook
** It also raises its PT by 25% to €90 ($101.02)
** Stock up around 3% to its highest price in more than a year
** "The fundamentals of the diagnostics/life sciences sector are improving," Equita notes
** It also sees Diasorin poised to benefit from the growth of its own diagnostics platforms, Liaison Nes and Plex, over the next few years
** The broker estimates Q3 revenue rising 7.6% y/y on an organic basis to €308 million and adj EBITDA of €99 million, expecting the group to offer a positive outlook for Q4
** Out of 16 analysts that cover Diasorin, seven rate the stock "buy,"​ four rate it "hold" and five​ maintain a "sell" recommendation - LSEG data

($1 = 0.8909 euros)

 (Reporting by Enrico Sciacovelli)
 ((Enrico.sciacovelli@thomsonreuters.com))